Lysophosphatidic Acid Signaling in Cancer Biology

Lysophosphatidic acid (LPA) is a small bioactive lipid mediator generated predominantly by the secreted enzyme autotaxin (ATX) through hydrolysis of lysophosphatidylcholine. Acting through at least six G protein-coupled receptors (LPAR1–6), LPA governs diverse cellular processes that underpin tumour initiation, progression and metastasis. In the cancer context, LPA signalling drives malignant cell proliferation, survival, motility and invasion, while simultaneously modulating the tumour microenvironment by influencing angiogenesis, fibrosis and immune cell recruitment. Crosstalk between LPAR pathways and key oncogenic networks—such as PI3K–AKT, Rho–ROCK and MAPK cascades—promotes epithelial–mesenchymal transition and enhances resistance to apoptosis. In parallel, LPA shapes antitumour immunity by reprogramming metabolic and differentiation states of T cells and suppressing cytotoxic function. Dysregulation of ATX expression or activity correlates with poor prognosis across multiple solid tumours, highlighting LPA signalling as a global driver of malignancy and a promising target for therapeutic intervention.

Research from Nature Portfolio

Recent studies have illuminated the immune-modulatory dimensions of ATX–LPA signalling in pancreatic and immunotherapeutic settings. One investigation in pancreatic ductal adenocarcinoma demonstrated that ATX activity suppresses intratumoural eosinophil accumulation by attenuating AP-1/c-Jun-driven expression of the eosinophil chemoattractant CCL11. Genetic or pharmacological inhibition of ATX restored eosinophil infiltration, enhanced local tumour cell apoptosis and correlated with improved survival, emphasising context-specific, antitumour immune effects of LPA blockade. In a separate analysis of adaptive immunity, LPA receptor 5 (LPAR5) signalling on CD8+ T cells was found to impose a tolerogenic, exhaustion-like state by orchestrating mitochondrial respiration, proton leak and reactive oxygen species production. Elevated LPA concentrations in the tumour milieu predicted poorer responses to immune checkpoint blockade, whereas disruption of LPAR5 signalling reinvigorated CD8+ T cell function, positioning LPA as a lipid-based immune checkpoint and a candidate target for combination immunotherapy.

Lysophosphatidic Acid Signaling in Cancer Biology publication trend

The graph below shows the total number of articles in lysophosphatidic acid signaling in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Autotaxin (ATX): A secreted lysophospholipase D enzyme responsible for converting lysophosphatidylcholine into the lipid mediator LPA.

Lysophosphatidic acid (LPA): A bioactive lipid that signals through G protein-coupled receptors to regulate cell proliferation, migration and survival.

LPA receptors (LPAR1–6): A family of G protein-coupled receptors mediating diverse downstream effects of LPA via heterotrimeric G proteins.

Immunosurveillance: The process by which immune cells detect and eliminate nascent tumour cells.

Metabolic reprogramming: Adaptation of cellular energy pathways to support proliferation, survival or specialised functions such as cytotoxicity.

Pro-apoptotic effectors: Proteins that promote programmed cell death in response to cellular stress or therapeutic agents.

References

1. Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression. Nature Cancer (2024).
2. Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity. Nature Communications (2023).
3. Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models. Journal of Experimental & Clinical Cancer Research (2023).
4. LPA receptor signaling: pharmacology, physiology, and pathophysiology. Journal of Lipid Research (2014).
5. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies. Signal Transduction and Targeted Therapy (2021).